Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) Short Interest Update

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) was the target of a large drop in short interest in March. As of March 31st, there was short interest totalling 20,700 shares, a drop of 62.9% from the March 15th total of 55,800 shares. Based on an average trading volume of 2,080,000 shares, the short-interest ratio is currently 0.0 days. Currently, 1.1% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lipella Pharmaceuticals stock. Virtu Financial LLC purchased a new position in shares of Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 13,310 shares of the company’s stock, valued at approximately $41,000. Virtu Financial LLC owned 1.10% of Lipella Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 74.31% of the company’s stock.

Lipella Pharmaceuticals Trading Down 0.8 %

NASDAQ LIPO traded down $0.02 on Tuesday, hitting $2.43. 10,941 shares of the company’s stock were exchanged, compared to its average volume of 702,058. Lipella Pharmaceuticals has a 52 week low of $1.97 and a 52 week high of $12.00. The stock has a 50-day moving average of $2.80 and a 200-day moving average of $2.94. The stock has a market cap of $6.19 million, a price-to-earnings ratio of -0.57 and a beta of 0.29.

Lipella Pharmaceuticals (NASDAQ:LIPO) last released its earnings results on Thursday, March 27th. The company reported ($1.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.43) by $1.24. Lipella Pharmaceuticals had a negative return on equity of 192.33% and a negative net margin of 882.82%. The firm had revenue of $0.17 million for the quarter.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).